Madrigal Pharmaceuticals, Inc.
MDGL· Nasdaq
Released Nov 4, 2021, before the open
10-Q filed Nov 4, 2021, 35 days after period end · 0001193125-21-319159
| Metric | Q3 2021 | Q3 2020 | Q3 2019 | Q3 2018 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$63.10M | -$57.96M | -$21.43M | -$8.51M |
| EPS Diluted |
Madrigal Pharmaceuticals, Inc. · CIK 1157601 · Engraved from SEC EDGAR
| -$3.79 |
| -$3.75 |
| -$1.39 |
| -$0.56 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.